Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Canine heart drug for UK

Ceva's new canine heart disease treatment Prilactone (spironolactone) is now available in the UK. The company claims that the product, which was first launched at the end of 2007, is the world's first aldosterone antagonist licensed for this indication. Prilactone has been shown to reduce the risk of mortality from heart disease by 65%. Fraser Broadfoot, Ceva's small animal veterinary advisor, says: "Clients are also noticing the improvements that Prilactone can cause to their dogs' clinical signs, which are often evident after just 10 days of treatment." The company has published a free information pack about the medicine. The product has also been launched in other European countries.


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts